BRCA1 and neoplasm: The clinical performance of F1CDx for BRCA1/2 classification was established based on available tumor analysis using FoundationFocusTM CDxBRCA, (which is a precursor to the F1CDx device) in the ARIEL2 and Study 10 clinical studies of rucaparib and via F1CDx in the clinical study D0818C00001 (SOLO1) of olaparib [83, 84].